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Background: Gastric cancer is a common malignancy worldwide and a common cause of death from cancer.
Despite recent advances in multimodality treatment and targeted therapy, complete resection remains the only
treatment that can lead to cure. This study was devised to investigate the technical feasibility, safety and oncologic
efficacy of laparoscopy-assisted gastrectomy for advanced gastric cancer without serosa invasion.
Methods: A retrospective matched cohort study was performed in south China comparing laparoscopy-assisted
gastrectomy and open gastrectomy for advanced gastric cancer without serosa invasion. Eighty-three patients with
advanced gastric cancer undergoing laparoscopy-assisted gastrectomy between January 2008 and December 2010
were enrolled. These patients were compared with 83 patients with advanced gastric cancer undergoing open
gastrectomy during the same period.
Results: There was no significant difference in clinicopathologic characteristics between the two groups. Regarding
perioperative characteristics, the operation time and time to ground activities did not differ between the two
groups, whereas the blood loss, transfused patient number, time to first flatus, time to resumption of diet, and
postoperative hospital stay were significantly less in laparoscopy-assisted gastrectomy than in open gastrectomy
(P <0.05). There was no statistically significant difference in postoperative morbidity and mortality. No significant
difference in the number of lymph nodes dissected was observed between these two groups. There was no
significant difference in the cumulative survival rate between the two groups.
Conclusion: Laparoscopy-assisted gastrectomy with D2 lymphadenectomy is a safe and feasible procedure for
advanced gastric cancer without serosa invasion. To be accepted as a choice treatment for advanced gastric cancer,
well-designed randomized controlled trials comparing short-term and long-term outcomes between
laparoscopy-assisted gastrectomy and open gastrectomy in a larger number of patients are necessary.
Keywords: Advanced gastric cancer, D2 lymphadenectomy, Laparoscopy-assisted gastrectomy, Matched cohort
study, Open gastrectomyBackground
Gastric cancer, a common malignancy worldwide, is the
second most common cause of death from cancer [1].
Despite recent advances in multimodality treatment and
targeted therapy, complete resection remains the only
treatment that can lead to cure. The use of laparoscopic* Correspondence: hcmlr2002@163.com
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reproduction in any medium, provided the ortechniques for early gastric cancer was first reported in
1994 [2] and, since then, many studies have reported
benefits of the technique such as reduced blood loss,
decreased pain, early recovery of bowel movements, and
a shorter hospital stay [3-5]. Since 1999, when the first
laparoscopy-assisted total gastrectomy with lymph node
dissection for gastric cancer was reported [6], the use of
laparoscopic gastrectomy for gastric cancer has been gen-
erally attempted in Japan and Korea, and the popularity of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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increased rapidly. However, application of laparoscopic
techniques for advanced gastric cancer (AGC) remains
controversial because of the technical difficulty of extra-
gastric lymphadenectomy and insufficient data related to
the procedure’s oncologic adequacy. In the present study,
we describe our experience with laparoscopy-assisted gas-
trectomy (LAG) in the treatment of AGC without serosa
invasion, and evaluate the feasibility, safety and oncologic
aspect of this approach through a matched cohort study.
Methods
Patients and materials
Between January 2008 and December 2010, 1,114 patients
diagnosed with primary gastric cancer were treated with
curative resection at the Department of Gastric Surgery,
Fujian Medical University Union Hospital, Fuzhou, China.
Of these patients, 632 underwent a laparoscopic approach
and 482 underwent an open technique. Patients were
informed of the possible complications of the procedure
and the advantages and disadvantages of a laparoscopic
compared with an open approach. Written informed con-
sent was obtained from all patients prior to the operation.
The type of gastric resection was determined according
to tumor location, size and depth of invasion. The D2
lymphadenectomies were undertaken according to the
Japanese Gastric Cancer Society’s guidelines for the treat-
ment of gastric cancer. Most nodal materials were separ-
ately dissected by the surgeons from the en bloc specimen
at the end of the procedure, and the remaining nodes were
identified and retrieved by specialized pathologists from
formalin-fixed surgical specimens without using any spe-
cific technique to increase nodal retrieval rate. Paraffin-
embedded nodes were stained with hematoxylin and
eosin, and examined microscopically for metastases by
specialized pathologists. Staging was done according to
the seventh edition of the International Union Against
Cancer tumor-node-metastasis classification [7].
Inclusion criteria were as follows: histologically con-
firmed adenocarcinoma of the stomach; performance
status of Eastern Cooperative Oncology Group score 0
to 1; no evidence of distant metastasis or invasion to
adjacent organs; and confinement without serosa inva-
sion (pT2, pT3). Patients in the laparoscopic group were
randomly matched to patients in the open group by age
(±5 years), gender, gastrectomy extent and depth of
invasion (pT2 and pT3) using a 1:1 interval matching
method. All the patients received fluorouracil-based
postoperative adjuvant chemotherapy for sixcycles, and no
patients underwent preoperative chemotherapy. Follow-
up was carried out by trained investigators through mail,
telephone calls, visits to patients or records of the patients’
consultations at the outpatient clinic. Most patient routine
follow-ups consisted of physical examination, laboratorytests (including carbohydrate antigen (CA)19-9, CA72-4
and carcinoembryonic antigenlevels), chest radiography,
abdominopelvic ultrasonography or computed tomography,
and an annual endoscopic examination. If gastrointestinal
symptoms were reported, an additional examination was
carried out. The survival time was from operation until the
date that the survival information was collected or the date
of death.
Statistical analysis
Statistical analysis was performed using SPSS.v16.0 for
Windows (SPSS Inc., Chicago, IL, USA). The statistical
analysis was conducted by Student’s t test or chi-square
test, and cumulative survival was compared by the
Kaplan–Meier method and log rank test. Values of
P<0.05 were considered statistically significant.
Surgical procedures
The laparoscopy-assisted total gastrectomy surgical pro-
cedure is described here. The surgical techniques for
lymph node dissection are principally the same in
laparoscopy-assisted distal gastrectomy (LADG). Gastro-
intestinal continuity was restored in a Roux-en-Y fashion
in total gastrectomy, and Billroth I or Billroth II recon-
struction in distal gastrectomy.
All the patients were placed in a supine position with
legs apart under general anesthesia. After the establish-
ment of a pneumoperitoneum at 12 mmHg, one initial
10-mm trocar for a laparoscope was inserted below the
umbilicus. The stomach and the peritoneal cavity were
inspected to rule out adjacent organ invasion and peri-
toneal seeding using a 30° forward oblique laparoscope.
A 10- to 12-mm port was inserted percutaneously in the
left upper quadrant as a major hand port. A 5-mm
trocar was placed at the contralateral site. Another two
5-mm trocars were respectively inserted in both the left
and right lower quadrants. The surgeon stood on the left
side of the patient, the assistant surgeon stood on the
right, and the other surgeon handling the laparoscopy
stood between the patient’s legs.
The gastrocolic ligament was divided using an ultra-
sonically activated shear along the border of the trans-
verse colon, thus including the greater omentum in the
specimen to be resected. The dissection moved to the
hepatic flexure and the pylorus. The right gastroepiploic
vein was divided between titanium clips flush with the
Henle’s trunk and ended up in the Fredet area, where
group 14v was removed. The right gastroepiploic artery
was vascularized and cut at its origin from the gas-
troduodenal artery with titanium clips, just above the
pancreatic head, to dissect group 6 (Figure 1). The stom-
ach was lifted headward to expose the gastropancreatic
fold. The left gastric vein was carefully prepared and
separately divided at the upper border of the pancreatic
Figure 1 Dissection of the lymph node numbers 14v and 6. MCV: middle colic vein; RCV: right colic vein; REGV: right gastroepiploic vein;
RGEA: right gastroepiploic artery; SMV: superior mesenteric vein.
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remove group 7. The lymph nodes along the proximal
splenic artery (group 11p) were removed. Subsequently,
the dissection was continued rightward along the artery
to remove the nodes along the celiac axis and the com-
mon hepatic artery (group 9, 8a) by retraction on the left
artery. The left gastric artery was cut between titanium
clips at its origin from the celiac axis. The right gastric
artery was divided at its origin from the common hep-
atic artery to dissect group 5. Along the border of the
liver, the lesser omentum was dissected and the lymph
nodes of the anterior region of the hepatoduodenal liga-
ment (group 12a) were dissected and removed (Figure 2).
Then, patients were tilted left-side-up about 20° to 30°
and subjected to a 20° head-up tilt. The surgeon moved
to stand between the patient’s legs; the assistant and the
camera operator were both on the patient’s right side.
The dissection of the gastrocolic ligament was continuedFigure 2 Dissection of the lymph node numbers 7, 8, 9, 11p and 12a.
gastric artery; LGV: left gastric vein; PHA: portal hepatic artery; PV: portal veitoward the spleen with the removal of group 4sb; subse-
quently, the dissection was continued upward along the
branches of splenic vessels to remove the nodes along
the splenic vessels (group 10, 11d); all short gastric
vessels (group 4sa) were divided close to the spleen
(Figure 3). Before gastric transection, the cardiac nodes
were dissected en bloc including right cardiac nodes
(group1) and left cardiac nodes (group 2). The first part
of the duodenum was dissected and then transected
2 cm below the pylorus with a 45-mm laparoscopic
cartridge linear stapling device (endo-GIA, US Surgical
Corporation, Norwalk, CT, USA) through a major hand
port. Gastrectomy and anastomosis were extracorpore-
ally performed using a handsewn method. The specimen
was pulled out of the peritoneal cavity through the small
laparotomy incision under the xiphoid (about 4 cm to
6 cm for distal gastrectomy and 6 cm to 8 cm for total
gastrectomy).CHA: common hepatic artery; GDA: gastroduodenal artery; LGA: left
n; SpA: splenic artery; SpV: splenic vein.
Figure 3 Dissection of the lymph node numbers 11d and 10. SpA: splenic artery; SpV: splenic vein.
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20-cm incision was made from the falciform process to
the periumbilical area. Distal gastrectomy and total gas-
trectomy with D2 lymph node dissection were per-
formed basically.
All the operations were performed by one surgeon team
with extensive experience both in open and laparoscopic
gastric cancer surgery. For patients with gastric cancer
located in the middle and upper third of the stomach,
total gastrectomy was performed with Roux-en-Y recon-
struction. In most patients with gastric cancer located in
the lower third of the stomach, distal gastrectomy were
performed with Billroth-I gastroduodenostomy. If the
tumor had invaded the pylorus or duodenal ampulla,
Billroth-II gastrojejunal anastomoses were produced. All
the reconstructionswere performed with a circular stapler
in an open manner.
Results
Clinicopathological characteristics of patients
Characteristics of the 166 case-matched patients (83 lap-
aroscopic versus 83 open) are listed in Table 1. There
were 142 men and 24 women, whose ages ranged from
28 to 85 years (61.3 ± 10.4 years). Both the LAG and
open gastrectomy (OG) groups had 71 men and 12
women, 30 patients in pT2 and 53 patients in pT3, and
37 patients with total gastrectomy and 46 patients with
distal gastrectomy. According to the International Union
Against Cancer classification of gastric cancer [7], 32
patients (19.3%) were at stage Ib, 37 patients (22.3%) at
stage IIa, 36 patients (21.7%) at stage IIb, 28 patients
(16.9%) at stage IIIa, and 33 patients (19.9%) at stage
IIIb. In the laparoscopic group, 24, 17 and 42 patients
had their tumors located in the upper-, middle- and
lower-third of the stomach, respectively, compared with
29, 11 and 43 patients in the open group. There was no
statistically significant difference found in the majorityof the demographic parameters between the two patient
populations (Table 1).
Perioperative outcomes
There were no significant differences in volume of ope-
ration time (P = 0.214) and time to ground activities
(P = 0.577) between the two groups. However, the blood
loss (P <0.001), transfused patient number (P = 0.025),
time of use of nonsteroidal anti-inflammatory drugs
(P = 0.006), time to first flatus (P = 0.038), time to resum-
ption of diet (P = 0.041), and postoperative hospital stay
(P <0.001) were significantly less in the LAG group than
in the OG group (Table 2).
Postoperative morbidity and mortality
The incidence of postoperative complications did not
differ between the two groups (10 patients in the LAG
group (12.0%) and 12 patients in the OG group (14.4%);
P = 0.819). One patient in the LAG group died during
their hospital stay because of complications arising from
an anastomotic leak, diagnosed as septic shock, which
developed into multiple organ disorder syndrome. Two
patients in the OG group died during their hospital stay:
one died of venous thromboembolism after surgery, the
other died of sepsis induced by duodenal stump leakage
(Table 3).
Lymph node retrieval in the laparoscopy-assisted and
open gastrectomy groups
The median of total lymph nodes was 28 per patient
(range, 14 to 62; mean 29.1 ± 9.2). The total number of
retrieved lymph nodes was not different between the two
groups (30.2 ± 10.1 in the LAG group versus 28.0 ± 8.1 in
the OG group; P = 0.103). No significant difference in
the numbers of retrieved lymph nodes at each station
was observed regardless of the gastrectomy extent
(Figures 4 and 5).











Age(years) 61.6 ± 10.3 61.1 ± 10.5 0.777
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group (n = 83)
P
Operation time (min) 212.7 ± 57.2 226.4 ± 63.5 0.214
Blood loss (ml) 78.4 ± 77.9 200.4 ± 218.3 0.000
Transfused patients 3 11 0.025
Time of use of
nonsteroidal anti-
inflammatory drugs
3.1 ± 1.2 5.8 ± 2.0 0.006
Time to ground
activities (days)
2.6 ± 1.1 2.7 ± 1.1 0.577
Time to first
flatus (days)
2.9 ± 1.2 4.0 ± 1.0 0.038
Time to resumption of
diet (days)
4.1 ± 1.5 5.5 ± 2.3 0.041
Postoperative hospital
stay (days)
14.2 ± 7.2 17.2 ± 5.0 0.000
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The median follow-up for the entire cohort was 23.0
months (range, 12 to 50 months). The follow-up rate
was 96.4%, with 160 patients involved (both LAG group
and OG group had 80 patients). The overall 1-year sur-
vival rate was 88.0% in the LAG group and 85.5% in the
OG group, and there was no significant difference in the
survival curve between the two groups (Figure 6).
Discussion
In the world literature, reports of laparoscopic techni-
ques for treating patients with early gastric cancer have
shown oncologic and long-term survival equivalency to
the open technique, with known benefits to a minimally
invasive approach [8,9]. For AGC, the Japanese Gastric
Cancer Association has presented complete D2 lympha-
denectomy including lymph nodes 10, 11p and 12a as
the standard therapy. In fact, curative resection of AGC
involves extended lymphadenectomy, which is well
accepted by Eastern Asian countries, such as Japan, Korea
and China, and some specialized centers in Europe,
though it remains controversial worldwide [10-12]. Never-
theless, laparoscopic D2 lymph node dissection has not
been widely investigated because it is considered to be
technically difficult and was performed only in a few insti-
tutes by highly experienced surgeons [13-16]. In our hos-
pital, D2 lymphadenectomy has been routinely performed.
An important consideration for new surgical proce-
dures is the learning curve faced by those who will be
performing them, as evidenced by experience from lap-
aroscopic procedures and general surgical techniques
[17-20]. The progress in the performance of a surgeon is
delineated as the so-called learning curve [21]. Like
other laparoscopic procedures, there is a learning curve





































Figure 4 The retrieved lymph nodes from laparoscopy-assisted total
There was no significant difference in the numbers of retrieved lymph nod
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perform this treatment with the tacit acceptance of a
lengthy operation time because they often perceive LAG
as a complicated technique inevitably subject to the
learning curve effect. A study by Kunisaki et al. [22]
focusing on the surgical learning curve of LADG by a
single surgeon showed the operating time was shortened
to 230 min after 60 cases. Lee et al. [23] reviewed the
cases of 257 patients who received distal gastrectomy
(included 136LADGs and 120 ODGs); they found that
the mean operation time was similar between the two
groups. The first LAG for early gastric cancer was
performed in April 2007 in our center. To ensure the
quality of our surgical procedure, we undertook this
study after ‘climbing up’ the learning curve, when we
performed more than 50 cases. In the present study,
there were no significant differences in operation time for
LAG and OG groups (212.7 ± 57.2 min versus 226.4 ±
63.5 min, P = 0.214). However, we found that patients
undergoing laparoscopy-assisted surgery had better post-
operative recovery, with less blood loss, quicker intestinal
functional recovery, and shorter hospital stay than those
undergoing conventional open surgery, similar to many
reported studies [24-26]. In addition, the safety of laparo-
scopic gastrectomy is very important for LAG. Kitano
et al. [27] reported a morbidity of 14.8% in a multicenter
trial with 1,294 patients undergoing laparoscopicgastrectomy (black bar) and open total gastrectomy (gray bar).
es at each station.
Figure 5 The retrieved lymph nodes from laparoscopy-assisted distal gastrectomy (black bar) and open distal gastrectomy (gray bar).
There was no significant difference in the numbers of retrieved lymph nodes at each station.
Figure 6 Comparison of cumulative survival rate of
laparoscopy-assisted gastrectomygroup and open gastrectomy
group by log-rank test (P >0.05).
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prospective randomized trial that included 179 patients
undergoing laparoscopy-assisted and 163 patients under-
going open distal gastrectomy, reported an 11.6% early
morbidity for the LAG group and 15.1% for the OG group,
with a mortality of 1% for the LAG group. However,in this
study there was no difference in the incidence of morbidity
between the LAG and OG groups (12.0% versus 14.4%,
P = 0.819). Therefore, LAG for gastric cancer may be
acceptable from this viewpoint. All of the above suggest
that LAG with D2 lymph node dissection for AGC without
serosa invasion is a safe and feasible choice.
Nowadays, more and more studies show that the pro-
cedure for gastrectomy with complete D2 lymph node
dissection is well established and accepted as a standard
practice for the treatment of AGC. So, besides the tech-
nical feasibility and favorable clinical outcomes of LAG,
the quality of lymphadenectomy is the most impor-
tant factor in performing LAG with D2 dissection. A
Japanese study found that adequate staging was possible
for 86% of the patients who underwent LADG with D2
dissection because more than 15 lymph nodes, the mini-
mum requirement for tumor-node-metastasis staging,
were retrieved. However, the total number of lymph nodes
and the nodes at station 4, 6, 9 and 11 were greater in the
ODG group than in the LADG group [29]. A similar study
conducted by Huscher et al. [30] showed that there was
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nodes at each station. Song et al. [31] enrolled 75 patients
who received standard D2 lymph nodes dissection
(44 underwent LADG, and 31 underwent ODG), and
found no significant differences in the total number of
retrieved lymph nodes or node stations between the two
groups. They suggested that LADG with D2 lymph node
dissection is oncologically compatible with OG. In the
current study, as a way of comparing the oncologic aspect
of quality control between the LAG and OG groups, we
compared the total number of retrieved lymph nodes and
numbers of nodes by their stations. The result showed
that no significant difference in the number of retrieved
lymph nodes or nodes at each station was observed re-
gardless of the gastrectomy extent. It is proved that LAG
with D2 lymph node dissection is technically possible, and
the number of retrieved lymph node was sufficient for
accurate staging.
The long-term oncologic result is very important in the
use of laparoscopic gastrectomy. Although few studies on
the outcome of LAG for AGC with T2 and T3 depth of
invasion have been published previously, the results of the
present study and other reports [32-34] show good out-
comes. Shuang et al. [32] compared 35 patients undergo-
ing LAG with 35 matched OG, and their results indicated
technical feasibility and equivalent short-term recurrence-
free survival of laparoscopic gastrectomy for gastric cancer
when compared with the open procedure. In this series,
the survival rates after LAG were excellent. The 1-year
survival rate after LAG was 88.0%, similar to the OG
group, and there was no significant difference in the
survival curve between the two groups.
Conclusions
Although the present study was not a randomized con-
trolled study and the follow-up period was not long
enough, the survival rate of patients with AGC who
underwent LAG was shown to be good. This study has
shown that LAG for AGC has several advantages over
OG, and LAG yielded similar oncologic outcomes in-
cluding complication rates and cumulative survival after
50 months of follow-up. To be accepted as a choice
treatment for AGC, it is necessary to conduct a well-
designed prospective trial to assess long-term outcomes.
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